Last Updated on October 17, 2024 by The Health Master
New Delhi: Drug firm Cipla Ltd said that the US health regulator has issued a warning letter to the company for its manufacturing facility in Goa.
“Further to our earlier communication on the Goa manufacturing facility inspection conducted from September 16-27, 2019 by the United States Food and Drug Administration (USFDA), the company has received a warning letter from USFDA,” Cipla Ltd said in a regulatory filing.
Also read: USFDA approves first generic version of Daraprim drug
The company further said that it remains committed to maintain highest standards of compliance and will work closely with the agency to comprehensively address all the observations.
Shares of Cipla were trading at Rs 418.30 a piece on BSE in the morning trade on BSE, down 1.66 per cent from its previous close.
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
